English
Spanish
French
Italian
German
NEWS
Latest News
Criteria for Hidradenitis Suppurativa Competence Centers
Today
An international Delphi consensus involving clinicians and patient representatives from 16 countries has established 23 core criteria for Hidradenitis Suppurativa Competence Centers. The recommendations provide a framework for delivering consistent, multidisciplinary, patient-centered HS care and may help improve access to specialized treatment worldwide.
Read more
Ambulatory Surgery May Be an Option for Troublesome Hidradenitis Suppurativa
July 10, 2026
Surgery isn't just a last resort anymore. A leading dermatologist explains why ambulatory surgery can offer faster relief for troublesome HS lesions, even for patients currently trying today's targeted biologic therapies. Learn when surgical intervention might be worth considering sooner rather than later.
Read more
Beyond the Surface: July 2026
2:00 p.m. Wednesday
Catch the latest from the Hidradenitis Suppurativa Foundation—SHSA 2026 in Tucson, new HS clinical guideline insights, updated resources, and upcoming deadlines you won't want to miss.
Read more
HS in Skin of Color: Bridging Gaps in Diagnosis, Treatment, and Equity
June 22, 2026
In this episode of Skin of Color Savvy, Tiffany Mayo, MD, Steven Daveluy, MD, and patient advocate Jasmine Ivanna Espy unpack the unique challenges of hidradenitis suppurativa (HS) in patients with skin of color, from delayed diagnosis to treatment hesitancy and access barriers. Blending clinical expertise with lived experience, the discussion highlights practical strategies to improve recognition, expand therapeutic confidence, and center patient voices in more equitable HS care.
Read more
The Emerging Role of Povorcitinib in Moderate to Severe Hidradenitis Suppurativa
June 16, 2026
A potential new chapter in hidradenitis suppurativa (HS) treatment is unfolding with povorcitinib, an oral JAK1-selective inhibitor showing promising phase 3 results. In patients with moderate to severe disease—many with prior biologic exposure—clinical response rates improved over time, alongside meaningful reductions in pain and draining tunnels. With generally favorable tolerability and the convenience of once-daily dosing, povorcitinib could help address persistent gaps in HS care and expand options beyond injectable biologics.
Read more
Expanding the HS Treatment Landscape: From Single-Pathway Therapy to Personalized Care
June 15, 2026
The hidradenitis suppurativa (HS) treatment landscape is evolving rapidly, with dozens of biologics and small-molecule therapies in development targeting multiple inflammatory pathways. In this interview, Leandra A. Barnes, MD, FAAD, discusses the shift toward more personalized, patient-centered care, the challenges of treatment dissatisfaction and access barriers, and the promise of emerging therapies that may help improve outcomes for people living with HS.
Read more
Q&A: How Does the Current HS Landscape Look? With Kiera Booth, MD
June 8, 2026
With new biologics expanding treatment options and additional therapies on the horizon, the hidradenitis suppurativa (HS) landscape is rapidly evolving. In this HCPLive Q&A, Kiera Booth, MD, discusses the importance of early diagnosis, individualized treatment selection, procedural approaches such as deroofing, and emerging therapies that may help improve outcomes for patients with HS.
Read more
Pediatric HS Insights: Colleen Cotton, MD, on Early Recognition, Referral, and Comprehensive Care
June 1, 2026
In this video series from Contemporary Pediatrics, Colleen Cotton, MD, FAAD, shares practical guidance on recognizing hidradenitis suppurativa (HS) in children and adolescents, identifying patients earlier through simple screening approaches, understanding key clinical signs, knowing when to refer, and supporting patients beyond medical treatment. These expert perspectives highlight opportunities to reduce diagnostic delays and improve outcomes for pediatric patients living with HS.
Read more
Advanced Antibiotic Strategies in Hidradenitis Suppurativa
May 22, 2026
In this Medscape podcast, expert clinicians discuss the real‑world challenges of caring for patients with hidradenitis suppurativa—covering timely diagnosis, evolving treatment strategies, and the importance of addressing quality‑of‑life burdens. The conversation offers practical insights to help clinicians improve outcomes and support patients over the long term.
Read more
Bimekizumab Shows Durable Responses in Psoriasis and HS Through 3 Years
May 18, 2026
New long‑term data presented at the 2026 AAD Annual Meeting suggest bimekizumab delivers durable disease control in hidradenitis suppurativa, with a growing proportion of patients remaining flare‑free through 3 years and no new safety signals observed. In this brief interview, Steven Daveluy, MD, discusses why extended assessment periods matter in HS, how sustained response influences treatment confidence, and what these findings may mean for long‑term patient care.
Read more